Cardio-renal cachexia syndromes (CRCS): Pathophysiological foundations of a vicious pathological circle

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 3, 2011, Pages 135-142

  Cicoira, Mariantonietta ^a   Anker, Stefan D ^b   Ronco, Claudio ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Cardio renal syndromes; Heart; Kidney

Indexed keywords

CACHEXIA; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEART FAILURE; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 84862876910     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0038-2     Document Type: Review

References (104)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121: e46-e215.
2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53: 557-73.
3. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006; 27: 569-81.
4. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne JR. High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007; 13: 422-30.
5. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004; 44: 1593-600.
6. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113: 671-8.
7. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997; 89: 1763-73.
8. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-43.
9. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009; 89: 381-410.
10. Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol. 2006; 21: 1807-14.
11. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349: 1050-3.
12. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003; 361: 1077-83.
13. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008; 34: 957-62.
14. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52: 1527-39.
15. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117: e25-e146.
16. Nohria A, Hasselbad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008; 51: 1268-74.
17. Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exhacerbation of Chronic Heart Failure (OPTIME-CHF). Circulation: Heart Fail. 2008; 1: 25-33.
18. Mullens W, Abrahams Z, Francis GS, Soko G, Taylo DO, Starling RG, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009; 53: 589-696.
19. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006; 1: 8-18.
20. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9: 1064-9.
21. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51: 1419-28.
22. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113: 671-8.
23. Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Satura N, Paganini EP. Isolation of 'myocardial depressant factor(s)' from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J. 1996; 42: M911-5.
24. Brady JP, Hasbargen JA. A review of the effects of correction of acidosis on nutrition in dialysis patients. Semin Dial. 2000; 13: 252-5.
25. Kelly KJ. Acute renal failure: much more than a kidney disease. Semin Nephrol. 2006; 26: 105-13.
26. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003; 14: 1549-58.
27. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-9.
28. Go AS, Chertow GM, Fan D, McCulloch E, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305.
29. McCollough PA. Why is chronic kidney disease the 'spoiler' for cardiovascular outcomes? J Am Coll Cardiol. 2003; 41: 725-8.
30. Parfrey PS, Foley RN, Harnett JD, Kent CM, Muraay DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996; 11: 1277-85.
31. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007; 18: 629-36.
32. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007; 18: 1307-15.
33. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164: 659-63.
34. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006; 17: 2034-47.
35. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity and outcome. J Am Soc Nephrol. 2003; 14: 1022-30.
36. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP Study. Crit Care Med. 2006; 34: 344-53.
37. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999; 27: 1775-80.
38. Pulkki KJ. Cytokines and cardiomyocyte death. Ann Med. 1997; 29: 339-43.
39. Bozkurt B, Kribbs SB, Clubb Jr FJ, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumour necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 98: 149-56.
40. Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989; 63: 709-13.
41. Freeman LM, Roubenoff R. The nutritional implications of cardiac cachexia. Nutr Review. 1994; 52: 340-7.
42. Evans WJ, Morley JE, Argilès J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
43. Kalanthar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodyalisis Int. 2006; 10: 315-25.
44. Kalanthar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003; 42: 864-81.
45. Pecoits-Filho R, Nordfors L, Lindholm B, Hoff CM, Schalling M, Stenvinkel P. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Kidney Int Suppl. 2003; 84: S162-7.
46. Herselman M, Esau N, Kruger JM, Labadarios D, Moosa MR. Relationship between body mass index and mortality in adults on maintenance hemodialysis: a systematic review. J Ren Nutr. 2010; 20: 281-92.
47. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007; 20: 566-9.
48. Obermayr RP, Temml C, Gutjahr G, Kainz A, Klauser-Braun R, Fugger R, et al. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrol Dial Transplant. 2009; 24: 2421-8.
49. Braunwald E. Clinical manifestation of heart failure. In: Braunwald E, editor. Heart disease. A textbook of cardiovascular medicine, vol. 1. Philadelphia: Saunders; 1984. p. 499.
50. MacGowan G, Mann D, Kormos R, Feldman A, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997; 79: 1128-31.
51. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997; 81: 187-95.
52. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999; 353: 1838-42.
53. Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323: 236-41.
54. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 1993; 70: 141-3.
55. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996; 93: 704-11.
56. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997; 96: 526-34.
57. Rauchhaus M, Doehner W, Francio DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000; 102: 3060-7.
58. Bozkurt B, Kribbs S, Clubb Jr FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97: 1382-91.
59. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes; involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996; 98: 2854-65.
60. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992; 257: 387-9.
61. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001; 15: 80-6.
62. Anker SD, Ponikowski P, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999; 20: 683-93.
63. Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993; 73: 205-9.
64. Anker SD, Volterrani M, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Q J Med. 1998; 91: 199-203.
65. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997; 29: 859-70.
66. Obisesan TO, Toth MJ, Yki-Jarvinen H. Free-fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1996; 77: 1250-2.
67. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989; 80: 299-305.
68. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implication. Clin Endocrinol. 2008; 69: 347-58.
69. Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997; 18: 259-69.
70. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994; 72: S36-9.
71. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zamboni M, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response to exercise in chronic heart failure patients. J Am Coll Cardiol. 2001; 37: 1808-12.
72. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski P, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997; 30: 1758-64.
73. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-60.
74. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001; 50: 2540-7.
75. Nagaya N, Uematsu M, Kosjima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001; 104: 2034-8.
76. Cicoira M, Kalra P, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003; 9: 219-26.
77. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, Von Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005; 46: 1019-26.
78. Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr. 1999; 129: 247S-51S.
79. Kalanthar-Zadeh K, Balakrishan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int. 2006; 10: 315-25.
80. Nomenclature consensus conference: kidney disease wasting. In: Fouque D, Kalantar-Zadeh K, editors. Organizing the XIII International Congress on Metabolism and Nutrition in Renal Disease, Merida, Yucatan, Mexico; 2006.
81. Kalantar-Zadeh K, Block G, McAllister CJ, Humphries MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004; 80: 299-307.
82. Campbell KL, MacLaughlin HL. Unintentional weight loss is an independent predictor of mortality in a hemodialysis population. J Ren Nutr. 2010; 20: 414-8.
83. Johansen KL. Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009; 16: 501-10.
84. Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr. 2006; 16: 208-11.
85. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007; 71: 146-52.
86. Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007; 17: 13-6.
87. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009; 19: 20-4.
88. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008; 11: 362-639.
89. Parks DA, Jacobson ED. Physiology of the splanchnic circulation. Arch Intern Med. 1985; 145: 1278-81.
90. Ding J, Cagnotti LJ, Huang Q, Xu DZ, Condon MR, Deitch EA. Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and DNA degradation. Shock. 2001; 16: 189-95.
91. Ritz E. Intestinal-renal syndrome: mirage or reality? Blood Purif. 2011; 31: 70-6.
92. Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V. Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis. Ren Fail. 2005; 27: 171-5.
93. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease-a new aspect of cardiovascular disease. Blood Purif. 2010; 29: 105-10.
94. Wollert K, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001; 6: 95-103.
95. Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev; 2011 (in press).
96. Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine. 2005; 32: 234-9.
97. Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004; 19: 2095-100.
98. Yoshimoto A, Mori K, Sugawara A, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002; 13: 2748-52.
99. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86: 5992-5.
100. Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007; 245: 480-6.
101. DeBoer MD, Zhu XX, Levasseur PR, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007; 148: 3004-12.
102. Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care. 2002; 5: 237-9.
103. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010; 15: 543-62.
104. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.